Bebtelovimab for COVID-19
Bebtelovimab for COVID-19
Highlights- Bebtelovimab reduced risk with low confidence for mortality, ICU admission, and hospitalization, and very low confidence for pooled analysis.
- However increased risk is seen with low confidence for progression.
- Efficacy is variant dependent. Bebtelovimab may have reduced or no activity for recent variants.
- Real-time updates and corrections with a consistent protocol for 227 treatments. Outcome specific analysis and combined evidence from all studies including treatment delay, a primary confounding factor.
Bebtelovimab COVID-19 studies
| Bamlanivimab/ etesevimab |
Casirivimab/ imdevimab |
Sotrovimab | Bebtelovimab | Tixagevimab/ cilgavimab |
|
|---|---|---|---|---|---|
| Alpha B.1.1.7 | |||||
| Beta/ Gamma BA1.351/ P.1 | |||||
| Delta B.1.617.2 | |||||
| Omicron BA.1/ BA.1.1 | |||||
| Omicron BA.2 | |||||
| Omicron BA.5 | |||||
| Omicron BA.4.6 | |||||
| Omicron BQ.1.1 |
Bebtelovimab for COVID-19: meta-analysis results
Random-effects meta-analysis. Relative risk with 95% CI. * p < 0.05, ** p < 0.01, *** p < 0.001.
Bebtelovimab COVID-19 studies
Bebtelovimab COVID-19 mortality results
Bebtelovimab COVID-19 ICU results
Bebtelovimab COVID-19 hospitalization results
Bebtelovimab COVID-19 progression results
Bebtelovimab COVID-19 viral clearance results
Bebtelovimab COVID-19 peer reviewed studies
COVID-19 RCT vs. observational results from 6,000+ studies
Bebtelovimab COVID-19 Randomized Controlled Trials
Bebtelovimab COVID-19 RCT mortality results
Media was 3.8× more likely to cover positive studies
19 positive studies were covered
paxlovid 5, remdesivir 3, casirivimab/imdevimab 2, convalescent plasma 2, molnupiravir 2, one each: antiandrogens, peginterferon lambda, sargramostim, tixagevimab/cilgavimab, tocilizumab
Only 6 negative studies were covered
remdesivir 3, one each: bamlanivimab/etesevimab, bebtelovimab, sotrovimab
Media bias for low-cost COVID‑19 treatments
Media covered only 0.8% of studies showing significantly lower COVID-19 risk
Only 5 positive studies were covered
one each: budesonide, cannabidiol, fluvoxamine, HCQ, vitamin D
34 negative studies were covered
HCQ 12, ivermectin 6, lopinavir/ritonavir 4, azithromycin 3, vitamin D 3, fluvoxamine 2, one each: ibuprofen, metformin, vitamin C, zinc
Early treatment is more effective: baloxavir marboxil
When studies showed efficacy
all studies RCTs only delay RCTs alone not yet significant · blue : pooled outcomes grey : specific outcomes · higher risk red: meta-analysis shows harm · efficacy: ≥10% improvement, p < 0.05, ≥3 studies · harm: RR > 1.0, p < 0.05, ≥3 studies
reduces riskBebtelovimab
increases risk →
reduces riskBebtelovimab
increases risk →
reduces riskBebtelovimab
increases risk →
Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to use additional treatments that are not tracked in the data (e.g., nasal/oral hygiene141,142, vitamin D143, etc.) — either because the physician recommending bebtelovimab also recommended them, or because the patient seeking out bebtelovimab is more likely to be familiar with the efficacy of additional treatments and more likely to take the time to use them. Therefore, these kind of studies may overestimate efficacy.
reduces riskBebtelovimab
increases risk →
reduces riskBebtelovimab
increases risk →
Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to use additional treatments that are not tracked in the data (e.g., nasal/oral hygiene141,142, vitamin D143, etc.) — either because the physician recommending bebtelovimab also recommended them, or because the patient seeking out bebtelovimab is more likely to be familiar with the efficacy of additional treatments and more likely to take the time to use them. Therefore, these kind of studies may overestimate efficacy.
reduces riskBebtelovimab
increases risk →
Confounding by treatment propensity. This study analyzes a population where only a fraction of eligible patients received the treatment. Patients receiving treatment may be more likely to follow other recommendations, more likely to receive additional care, and more likely to use additional treatments that are not tracked in the data (e.g., nasal/oral hygiene141,142, vitamin D143, etc.) — either because the physician recommending bebtelovimab also recommended them, or because the patient seeking out bebtelovimab is more likely to be familiar with the efficacy of additional treatments and more likely to take the time to use them. Therefore, these kind of studies may overestimate efficacy.

| Dougan, 3/12/2022, Randomized Controlled Trial, USA, preprint, 22 authors, study period 19 April, 2021 - 19 July, 2021, average treatment delay 3.0 days, trial NCT04634409 (history) (BLAZE-4). | risk of hospitalization, 27.0% higher, RR 1.27, p = 1.00, treatment 5 of 252 (2.0%), control 2 of 128 (1.6%), combined bebtelovimab arms. |
| risk of hospitalization, 2.4% higher, RR 1.02, p = 1.00, treatment 2 of 125 (1.6%), control 2 of 128 (1.6%), bebtelovimab only. | |
| relative viral load reduction, 4.0% better, RR 0.96, p < 0.001, treatment mean 3.77 (±0.21) n=125, control mean 3.62 (±0.2) n=128, day 7. | |
| relative viral load reduction, 29.7% better, RR 0.70, p < 0.001, treatment mean 3.03 (±0.19) n=125, control mean 2.13 (±0.19) n=128, day 5. | |
| relative viral load reduction, 15.4% better, RR 0.85, p < 0.001, treatment mean 1.43 (±0.2) n=125, control mean 1.21 (±0.2) n=128, day 3. | |
| risk of no viral clearance, 38.6% lower, RR 0.61, p = 0.12, treatment 15 of 125 (12.0%), control 25 of 128 (19.5%), NNT 13, persistently high viral load, day 7, primary outcome. | |
| Dryden-Peterson, 10/27/2022, retrospective, USA, peer-reviewed, 7 authors, study period 16 March, 2022 - 31 May, 2022, average treatment delay 3.0 days. | risk of death, 85.7% lower, RR 0.14, p = 0.25, treatment 0 of 377 (0.0%), control 3 of 377 (0.8%), NNT 126, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm). |
| risk of death/hospitalization, 43.0% lower, RR 0.57, p = 0.14, treatment 10 of 377 (2.7%), control 17 of 377 (4.5%), NNT 54. | |
| risk of hospitalization, 28.6% lower, RR 0.71, p = 0.53, treatment 10 of 377 (2.7%), control 14 of 377 (3.7%), NNT 94. | |
| Kip, 4/4/2023, retrospective, USA, peer-reviewed, 16 authors, study period 8 December, 2020 - 31 August, 2022. | risk of death/hospitalization, 20.0% lower, RR 0.80, p = 0.65, treatment 6 of 157 (3.8%), control 15 of 314 (4.8%), NNT 105, omicron variant, day 28. |
| Lilly, 2/12/2022, Randomized Controlled Trial, USA, preprint, 1 author, study period 29 October, 2020 - 18 October, 2021, average treatment delay 3.6 days, trial NCT04634409 (history). | risk of death, 150.8% higher, RR 2.51, p = 1.00, treatment 1 of 252 (0.4%), control 0 of 128 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), combined bebtelovimab arms. |
| risk of death, 200.8% higher, RR 3.01, p = 0.50, treatment 1 of 127 (0.8%), control 0 of 128 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), bamlanivimab, etesevimab, and bebtelovimab. | |
| risk of hospitalization, 27.0% higher, RR 1.27, p = 1.00, treatment 5 of 252 (2.0%), control 2 of 128 (1.6%), combined bebtelovimab arms. | |
| risk of hospitalization, 51.2% higher, RR 1.51, p = 0.68, treatment 3 of 127 (2.4%), control 2 of 128 (1.6%), bamlanivimab, etesevimab, and bebtelovimab. | |
| risk of hospitalization, 2.4% higher, RR 1.02, p = 1.00, treatment 2 of 125 (1.6%), control 2 of 128 (1.6%), bebtelovimab. | |
| risk of no viral clearance, 35.5% lower, RR 0.64, p = 0.07, treatment 33 of 252 (13.1%), control 26 of 128 (20.3%), NNT 14, day 7 persistently high viral load, combined bebtelovimab arms, primary outcome. | |
| risk of no viral clearance, 38.0% lower, RR 0.62, p = 0.13, treatment 16 of 127 (12.6%), control 26 of 128 (20.3%), NNT 13, day 7 persistently high viral load, bamlanivimab, etesevimab, and bebtelovimab, primary outcome. | |
| risk of no viral clearance, 33.0% lower, RR 0.67, p = 0.18, treatment 17 of 125 (13.6%), control 26 of 128 (20.3%), NNT 15, day 7 persistently high viral load, bebtelovimab, primary outcome. | |
| Molina, 4/16/2023, retrospective, USA, peer-reviewed, 11 authors, study period 6 April, 2022 - 11 October, 2022. | risk of death, 57.0% lower, RR 0.43, p = 0.14, treatment 3 of 3,739 (0.1%), control 11 of 5,423 (0.2%), NNT 816, adjusted per study, odds ratio converted to relative risk, propensity score matching, multivariable. |
| risk of ICU admission, 58.6% lower, RR 0.41, p = 0.05, treatment 6 of 3,739 (0.2%), control 21 of 5,423 (0.4%), NNT 441. | |
| risk of hospitalization, 55.5% lower, RR 0.44, p < 0.001, treatment 38 of 3,739 (1.0%), control 107 of 5,423 (2.0%), NNT 105, adjusted per study, odds ratio converted to relative risk, COVID-19, propensity score matching, multivariable. | |
| risk of hospitalization, 46.5% lower, RR 0.54, p < 0.001, treatment 48 of 3,739 (1.3%), control 116 of 5,423 (2.1%), NNT 117, adjusted per study, odds ratio converted to relative risk, all cause, propensity score matching, multivariable. | |
| risk of progression, 32.6% higher, RR 1.33, p = 0.001, treatment 260 of 3,739 (7.0%), control 275 of 5,423 (5.1%), adjusted per study, odds ratio converted to relative risk, ED visit, propensity score matching, multivariable. | |
| Sridhara, 4/28/2023, retrospective, USA, peer-reviewed, 13 authors, study period 5 April, 2022 - 1 August, 2022. | risk of death, 85.7% lower, RR 0.14, p = 0.25, treatment 0 of 1,091 (0.0%), control 3 of 1,091 (0.3%), NNT 364, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), propensity score matching, day 30. |
| risk of death/hospitalization, 25.0% lower, HR 0.75, p = 0.31, treatment 24 of 1,091 (2.2%), control 28 of 1,091 (2.6%), adjusted per study, propensity score matching, multivariable, Cox proportional hazards. | |
| risk of hospitalization, 11.1% lower, RR 0.89, p = 0.78, treatment 24 of 1,091 (2.2%), control 27 of 1,091 (2.5%), NNT 364, propensity score matching, day 30RETRO. |

